Skip to content
value.today
Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO
$155 Mmarket cap on Oct 26, 2026-42.8% since Jan 2024
1M
-42.0%
Compare
World rank
#17,182
Revenue
$102 M
For year ending December-2025
Net income
$-191 M
-186.5% margin
SEC filing
Employees
224
As on 2021
value.today research

Sutro Biopharma, Inc. in brief

Sutro Biopharma, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $155 M on 26 October 2026, which makes it the 17,182nd largest listed company in the world and the 3,296th largest in the USA on this site. In the year to December 2025 it had sales of $102 M and a net loss of $191 M. It employs about 224 people and Jane Chung is its chief executive. Its shares trade under the symbol STRO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sutro Biopharma, Inc.

Healthcare sector company which develops therapies related to Cancer. Headquarters is in California, USA.

Sutro Biopharma, Inc. timeline

4 events, 2006–2023
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2007
  4. ✎
    Renamed Sutro Biopharma Inc
    Formerly Fundamental Applied Biology Inc.
  5. 2018
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 27 September 2018; shares registered for exchange trading on 18 September 2018.
  7. 2023
  8. 💰
    Record revenue of $154 million
    FY2023, the highest of the 8 years on record.

Events of Sutro Biopharma, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$267 M$535 M$802 M$1.1 B2020202120222023202420252026

World rank over time

▼ down 2,573 places since 2020
2020-01-01: #14657#14,65720202021-01-01: #7982#7,98220212022-01-07: #13664#13,66420222022-12-25: #13959#13,95920222023-07-30: #16412#16,41220232024-01-05: #16334#16,33420242026-03-08: #7562#7,56220262026-08-01: #13740#13,74020262026-09-30: #15307#15,30720262026-10-26: #17230#17,2302026

Rank in USA: #3,035 (Jan 2020) · #2,227 (Jan 2021) · #3,306 (Jan 2022) · #2,866 (Dec 2022) · #3,339 (Jul 2023) · #3,017 (Jan 2024) · #1,333 (Mar 2026) · #2,777 (Aug 2026) · #2,961 (Sep 2026) · #3,300 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
1.5×
Price / book
—
Free cash flow yield
7.2%
Net margin
-186.5%
Operating margin
-154.5%
Return on equity
—
Liabilities / assets
176.2%
Net debt
$-65M
Revenue growth
+65.2%
R&D / revenue
162.4%
Revenue per employee
$458 K
Profit per employee
$-853 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $38M, net income $-35M$38MFY18Fiscal year ending Dec 2019: revenue $43M, net income $-119M$43MFY19Fiscal year ending Dec 2020: revenue $43M, net income $-32M$43MFY20Fiscal year ending Dec 2021: revenue $62M, net income $-106M$62MFY21Fiscal year ending Dec 2022: revenue $68M, net income $-119M$68MFY22Fiscal year ending Dec 2023: revenue $154M, net income $-107M$154MFY23Fiscal year ending Dec 2024: revenue $62M, net income $-227M$62MFY24Fiscal year ending Dec 2025: revenue $102M, net income $-191M$102MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$102M+65.2%$-158M$-191M-186.5%
Dec 2024$62M-59.6%$-238M$-227M-366.6%
Dec 2023$154M+126.8%$-89M$-107M-69.5%
Dec 2022$68M+9.5%$-129M$-119M-175.9%
Dec 2021$62M+44.9%$-99M$-106M-170.6%
Dec 2020$43M-0.0%$-71M$-32M-75.2%
Dec 2019$43M+11.2%$-55M$-119M-278.9%
Dec 2018$38M—$-37M$-35M-91.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-177M——$-22.49—
Dec 2024$-192M——$-29.40—
Dec 2023$-112M——$-1.78—
Dec 2022$4M——$-2.35—
Dec 2021$-82M——$-2.29—
Dec 2020$-68M——$-0.99—
Dec 2019$-65M——$-2.43—
Dec 2018$13M$2M$11M$-6.13—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $15M, net income $-72M$15MDec ’24Three months to Mar 2025: revenue $17M, net income $-76M$17MMar ’25Three months to Jun 2025: revenue $64M, net income $-12M$64MJun ’25Three months to Sep 2025: revenue $10M, net income $-57M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue $12M, net income $-47M$12MDec ’25Three months to Mar 2026: revenue $15M, net income $-38M$15MMar ’26Three months to Jun 2026: revenue $10M, net income $-39M$10MJun ’26Three months to Sep 2026: revenue $9M, net income $-31M$9MSep ’26

Latest quarter to Sep 2026: revenue $9M (-6.1% on a year earlier), net income $-31M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Sutro Biopharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$102 M
Operating income
$-158 M
Net income
$-191 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$174 M
Total liabilities
$306 M
Total equity
$-132 M

As of December-2025

Top 100 institutional investors in Sutro Biopharma, Inc.#

As of Sep 30, 2026
103 institutions held 16.7 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 54.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Sutro Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BVF Inc/il1,251,7880 (0.00%)7.54%$20 MNov 16, 2026
2BlackRock, Inc.1,178,196+55,541 (+4.95%)7.10%$19 MNov 13, 2026
3Affinity Asset Advisors, LLC1,152,487-20,000 (-1.71%)6.94%$19 MNov 13, 2026
4Samsara Biocapital, LLC1,062,8720 (0.00%)6.40%$17 MNov 16, 2026
5Perceptive Advisors LLC970,846-334,000 (-25.60%)5.85%$16 MNov 16, 2026
6Kynam Capital Management, LP872,5580 (0.00%)5.26%$14 MNov 16, 2026
7Orbimed Advisors LLC743,9440 (0.00%)4.48%$12 MNov 16, 2026
8Vanguard Capital Management LLC676,926-17,293 (-2.49%)4.08%$11 MNov 13, 2026
9Acadian Asset Management LLC557,868+184,029 (+49.23%)3.36%$9 MNov 9, 2026
10Velan Capital Investment Management LP510,038-2,122 (-0.41%)3.07%$8 MNov 16, 2026
11Goldman Sachs Group Inc496,794+347,578 (+232.94%)2.99%$8 MNov 16, 2026
12T. Rowe Price Investment Management, Inc.411,655New2.48%$7 MNov 16, 2026
13Qube Research & Technologies Ltd379,290+272,680 (+255.77%)2.28%$6 MNov 13, 2026
14Geode Capital Management, LLC365,851-23,841 (-6.12%)2.20%$6 MNov 6, 2026
15Two Sigma Investments, LP358,075+156,387 (+77.54%)2.16%$6 MNov 16, 2026
16Woodline Partners LP350,136-107,893 (-23.56%)2.11%$6 MNov 16, 2026
17Ameriprise Financial Inc347,947+103,278 (+42.21%)2.10%$6 MNov 16, 2026
18State Street Corp324,477+18,498 (+6.05%)1.95%$5 MNov 12, 2026
19Marshall Wace, LLP317,964+142,718 (+81.44%)1.92%$5 MNov 13, 2026
20Citadel Advisors LLC289,939+187,974 (+184.35%)1.75%$5 MNov 16, 2026
21Vanguard Portfolio Management LLC282,764+85,202 (+43.13%)1.70%$5 MNov 13, 2026
22Merck & Co., Inc.272,3510 (0.00%)1.64%$4 MNov 13, 2026
23ADAR1 Capital Management, LLC267,067-136,947 (-33.90%)1.61%$4 MNov 16, 2026
24Elmind Capital, LP228,265+196,228 (+612.50%)1.38%$4 MNov 16, 2026
25KVP Capital Advisors, LP226,5750 (0.00%)1.36%$4 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Sutro Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jpmorgan Chase & Co225,840+66,213 (+41.48%)1.36%$4 MNov 12, 2026
27Balyasny Asset Management L.P.223,114-488,048 (-68.63%)1.34%$4 MNov 16, 2026
28Ra Capital Management, L.P.210,934New1.27%$3 MNov 16, 2026
29FMR LLC171,245+169,906 (+12689.02%)1.03%$3 MNov 10, 2026
30Point72 Asset Management, L.P.136,793-101,034 (-42.48%)0.82%$2 MNov 16, 2026
31UBS Group AG115,058-93,454 (-44.82%)0.69%$2 MNov 10, 2026
32Northern Trust Corp114,731-11,202 (-8.90%)0.69%$2 MNov 16, 2026
33Vanguard Fiduciary Trust Co100,036-4,196 (-4.03%)0.60%$2 MNov 13, 2026
34Seven Fleet Capital Management LP99,894-59,224 (-37.22%)0.60%$2 MNov 16, 2026
35Y-Intercept (Hong Kong) Ltd90,536+34,657 (+62.02%)0.55%$1 MOct 16, 2026
36Jacobs Levy Equity Management, Inc90,381New0.54%$1 MNov 16, 2026
37Renaissance Technologies LLC87,247+923 (+1.07%)0.53%$1 MNov 12, 2026
38Charles Schwab Investment Management Inc73,732+24,430 (+49.55%)0.44%$1 MNov 16, 2026
39Mackenzie Financial Corp68,513-26,254 (-27.70%)0.41%$1 MNov 2, 2026
40Invesco Ltd.64,885+7,580 (+13.23%)0.39%$1 MNov 12, 2026
41BNP Paribas Financial Markets62,306+34,923 (+127.54%)0.38%$1 MNov 12, 2026
42Wellington Management Group LLP58,319+47,519 (+439.99%)0.35%$1 MNov 16, 2026
43Morgan Stanley55,238+42,882 (+347.05%)0.33%$1 MNov 13, 2026
44Barclays PLC51,098+14,144 (+38.27%)0.31%$1 MNov 6, 2026
45Bank of New York Mellon Corp41,3690 (0.00%)0.25%$1 MNov 5, 2026
46Fisher Asset Management, LLC35,2950 (0.00%)0.21%$1 MNov 6, 2026
47Nuveen, LLC34,872-133,125 (-79.24%)0.21%$1 MNov 10, 2026
48XTX Topco Ltd33,271-18,898 (-36.22%)0.20%$1 MNov 16, 2026
49HSBC Holdings PLC29,853+23,619 (+378.87%)0.18%$0 MNov 16, 2026
50Susquehanna Portfolio Strategies, LLC28,242New0.17%$0 MNov 16, 2026
51Squarepoint Ops LLC28,193-27,346 (-49.24%)0.17%$0 MNov 9, 2026
52Los Angeles Capital Management LLC26,706New0.16%$0 MNov 12, 2026
53Massachusetts Financial Services Co /ma/25,850New0.16%$0 MNov 12, 2026
54Verdad Advisers, LP25,499+19,099 (+298.42%)0.15%$0 MNov 16, 2026
55Acuta Capital Partners, LLC25,290-244,961 (-90.64%)0.15%$0 MNov 16, 2026
56Millennium Management LLC24,754-341,218 (-93.24%)0.15%$0 MNov 16, 2026
57Man Group plc24,098New0.15%$0 MNov 16, 2026
58Franklin Templeton Inc21,774New0.13%$0 MNov 12, 2026
59Rhumbline Advisers21,525+897 (+4.35%)0.13%$0 MNov 10, 2026
60Engineers Gate Manager LP19,228New0.12%$0 MNov 16, 2026
61Public Employees Retirement System Of Ohio18,277New0.11%$0 MNov 16, 2026
62Bank Of America Corp /de/17,578-18,562 (-51.36%)0.11%$0 MNov 16, 2026
63Connor, Clark & Lunn Investment Management Ltd.17,051New0.10%$0 MNov 10, 2026
64Quadrature Capital Ltd16,866New0.10%$0 MNov 13, 2026
65RBF Capital, LLC15,2720 (0.00%)0.09%$0 MNov 13, 2026
66TD Asset Management Inc14,554New0.09%$0 MNov 13, 2026
67Deutsche Bank AG\13,603-1,960 (-12.59%)0.08%$0 MNov 6, 2026
68Price T Rowe Associates Inc /MD/13,5970 (0.00%)0.08%$0 MNov 16, 2026
69Susquehanna Fundamental Investments, LLC13,508New0.08%$0 MNov 16, 2026
70Jump Financial, LLC12,900New0.08%$0 MNov 13, 2026
71Achmea Investment Management B.V.12,198New0.07%$0 MOct 30, 2026
72Jain Global LLC11,675New0.07%$0 MNov 16, 2026
73SEI Investments Co10,962-5,425 (-33.11%)0.07%$0 MNov 10, 2026
74Persistent Asset Partners Ltd9,409+2,840 (+43.23%)0.06%$0 MNov 13, 2026
75MetLife Investment Management, LLC9,4010 (0.00%)0.06%$0 MNov 16, 2026
76MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.6,881-432 (-5.91%)0.04%$0 MNov 16, 2026
77New York State Common Retirement Fund5,6000 (0.00%)0.03%$0 MNov 17, 2026
78Vanguard Global Advisers, LLC5,508+63 (+1.16%)0.03%$0 MNov 13, 2026
79Police & Firemen's Retirement System of New Jersey4,7040 (0.00%)0.03%$0 MNov 9, 2026
80Employees Retirement System of Texas4,679New0.03%$0 MNov 10, 2026
81Tower Research Capital LLC (TRC)3,861+2,995 (+345.84%)0.02%$0 MNov 16, 2026
82Legal & General Group Plc3,206-256 (-7.39%)0.02%$0 MNov 16, 2026
83Wells Fargo & Company/mn3,039-10,505 (-77.56%)0.02%$0 MNov 16, 2026
84State of Wyoming2,082+464 (+28.68%)0.01%$0 MOct 28, 2026
85Ameritas Investment Partners, Inc.1,4480 (0.00%)0.01%$0 MNov 13, 2026
86UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,442New0.01%$0 MNov 16, 2026
87Russell Investments Group, Ltd.1,442+167 (+13.10%)0.01%$0 MNov 6, 2026
88Citigroup Inc1,189-6,267 (-84.05%)0.01%$0 MNov 4, 2026
89FNY Investment Advisers, LLC1,0000 (0.00%)0.01%$0 MOct 16, 2026
90Royal Bank Of Canada759+72 (+10.48%)0.00%$0 MNov 16, 2026
91Owl Creek Wealth Partners LLC4910 (0.00%)0.00%$0 MOct 20, 2026
92Sterling Capital Management LLC317+36 (+12.81%)0.00%$0 MOct 22, 2026
93California State Teachers Retirement System2200 (0.00%)0.00%$0 MNov 13, 2026
94Physician Wealth Advisors, Inc.1820 (0.00%)0.00%$0 MOct 20, 2026
95GAMMA Investing LLC140New0.00%$0 MOct 8, 2026
96Osaic Holdings, Inc.1000 (0.00%)0.00%$0 MNov 12, 2026
97Arax Advisory Partners67+51 (+318.75%)0.00%$0 MNov 12, 2026
98Nisa Investment Advisors, LLC440 (0.00%)0.00%$0 MOct 20, 2026
99HighMark Wealth Management LLC230 (0.00%)0.00%$0 MNov 17, 2026
100Allworth Financial LP8New0.00%$0 MNov 17, 2026

All 103 institutional investors, with who bought and sold →

Mutual funds holding Sutro Biopharma, Inc.#

80 funds hold shares worth $87 M (about 16.9% of the company). Since their previous reports 71 added shares and 7 sold, buying $35 M net.
Mutual funds holding Sutro Biopharma, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC585,262$19 M3.5%1.1%−18%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.501,524$17 M3.0%<0.01%−5.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors326,271$11 M2.0%0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.177,208$6 M1.1%<0.01%+4.8%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC173,722$4 M1.0%0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors98,529$3 M0.59%0.02%newJun 30, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC126,290$3 M0.76%0.08%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC78,053$2 M0.47%<0.01%+78%May 31, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.60,304$2 M0.36%0.18%newJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.77,195$2 M0.46%0.18%newJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.66,530$2 M0.40%0.12%newJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors47,714$2 M0.29%0.10%+130%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.38,737$1 M0.23%0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC27,815$1 M0.17%<0.01%+107%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC23,951$1 M0.14%0.01%newJun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.28,467$1 M0.17%<0.01%newJul 31, 2026
🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc.28,234$1 M0.17%0.10%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC23,004$1 M0.14%<0.01%+107%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC18,817$1 M0.11%0.03%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors18,719$1 M0.11%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC21,156$1 M0.13%0.01%newJul 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.14,128$0 M0.09%0.03%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC13,899$0 M0.08%0.01%newJun 30, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation13,437$0 M0.08%0.18%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC16,529$0 M0.10%0.01%−3.7%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation11,500$0 M0.07%0.02%newJun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS10,345$0 M0.06%0.16%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC13,975$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.13,476$0 M0.08%0.10%newJul 31, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC8,860$0 M0.05%0.09%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.8,468$0 M0.05%<0.01%−9.3%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.8,229$0 M0.05%0.02%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.10,500$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.7,075$0 M0.04%<0.01%−20%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.6,882$0 M0.04%0.10%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.5,900$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC7,595$0 M0.05%0.01%newJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC5,330$0 M0.03%0.02%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,773$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC4,574$0 M0.03%0.02%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,177$0 M0.03%<0.01%+13%May 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors4,102$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS3,561$0 M0.02%0.02%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC3,289$0 M0.02%0.02%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,173$0 M0.02%0.05%+114%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC3,000$0 M0.02%0.07%no changeJun 30, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC2,842$0 M0.02%0.06%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,690$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,690$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.2,503$0 M0.02%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.2,406$0 M0.01%0.02%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC2,347$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.2,341$0 M0.01%<0.01%−43%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC2,781$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC1,960$0 M0.01%0.02%newJun 30, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC1,925$0 M0.01%0.05%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,734$0 M0.01%0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,701$0 M0.01%0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,448$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,868$0 M0.01%0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,275$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,648$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC1,566$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,104$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC1,070$0 M<0.01%<0.01%+39%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,412$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC884$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC712$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC933$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC500$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC445$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.403$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS505$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC299$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC270$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.252$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC179$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.151$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC189$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC92$0 M<0.01%<0.01%+114%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 80 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Sutro Biopharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
$90 K-$61 K$0Jan 2024: bought $0 (0 trades), sold $61 K (1 trades)Jan 24Oct 2025: bought $90 K (5 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Sutro Biopharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Hans-Peter GerberCHIEF SCIENTIFIC OFFICEROption exercise+3,750——13,712Form 4
filed Hans-Peter GerberCHIEF SCIENTIFIC OFFICERShares withheld for tax-1,345$15.34$21 K12,367Form 4
filed Gregory K. ChowCFOOption exercise+2,500——4,725Form 4
filed Jane ChungChief Executive Officer, DirectorOption exercise+788——21,567Form 4
filed David PaulingChief Admin. Ofcr. & GCOption exercise+675——10,025Form 4
filed Jane ChungChief Executive Officer, DirectorShares withheld for tax-282$21.31$6 K21,285Form 4
filed David PaulingChief Admin. Ofcr. & GCShares withheld for tax-277$21.31$6 K9,748Form 4
filed Hans-Peter GerberCHIEF SCIENTIFIC OFFICEROption exercise+2,843——10,688Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sutro Biopharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.3 M
26.3% of shares · 6.26 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Trading halts

  • 2025-12-03 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 93 shares at $9.33
  • : 5,090 shares at $11.54
  • : 6,050 shares at $10.94
  • : 2,640 shares at $10.52
  • : 8 shares at $16.10

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sutro Biopharma, Inc. scorecard#

Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
    • ✓Free cash flow yield above 5%7.2%Free cash flow is 7.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year65.2%Revenue up 65.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years14.8%14.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median14.8%14.8% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-22.49 vs -29.40Diluted EPS -22.49 in fiscal 2025 against -29.40 the year before (report's currency).
    • ✗Net income higher than five years earlier-$191 M-$191 M in fiscal 2025 against -$32 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$191 MNet income -$191 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-154.5%-154.5% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-154.5%-154.5% in fiscal 2025 against -190.3% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-9.47Z-score -9.47 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Sutro Biopharma, Inc.'s statements, beside the median of Biotechnology.

Sutro Biopharma, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-154.5%-60.5%
Net margin-186.5%-68.9%
Revenue growth, 3 years a year14.8%12.9%
Revenue growth65.2%15.8%

2of 7on the Piotroski tests of financial strength

  • Net loss of $191 million, the 9th loss-making year in a row.
  • The share count rose 9.8% in the year.
  • Shareholders' equity is negative: -$132 million.

Sutro Biopharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sutro Biopharma, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue1026215468624343385260
Research and development1662521801371047766545544
General and administrative41486360563733211615
Operating expenses26130024319716011498767158
Operating income−158−238−89−129−99−71−55−37−191.4
Interest expense and finance costs——1.32.42.62.31.11.60.60
Net interest income——————−4.4———
Other non-operating income (expense)———————1.9−0.10.1
Income before tax−191−225−89−117−106−32————
Income tax−0.12.4182.500.1r000—
Net income including minority interests−191−227−107−119−106−32−56−35−201.7
Net income attributable to shareholders−191−227−107−119−106−32−56−35−201.7
Earnings per share, basic-22.49-29.40r-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00
Earnings per share, diluted-22.49-29.40r-1.78-2.35-2.29-0.99-2.43-6.13-43.950.00
Shares, weighted average (basic)8.57.7r60514633————
Shares, weighted average (diluted)8.57.7r60514633235.80.40.4
Balance sheet
Cash and cash equivalents581906947302065.01252212
Short-term investments8312726425513012011379——
Receivables4.08.6367.1125.66.32.51.6—
Other current assets5.5189.8128.14.54.43.02.0—
Current assets15134342235321937812921026—
Property, plant and equipment1118222523139.61114—
Right-of-use (leased) assets1118232629—————
Total assets17438747140734139415622341—
Accounts payable7.6109.44.86.0r5.55.63.12.9—
Debt due within a year——4.1139.4—1.04.715r—
Current liabilities7513294674230333632—
Long-term debt——03.816258.910——
Lease liabilities (non-current)7.916233031—————
Total liabilities3063433211908962599247—
Retained earnings−978−787−559−453−333−228−196−150−115—
Shareholders' equity−1324515021725333298132−109−91
Total liabilities and equity17438747140734139415622341—
Shares outstanding8.68.3r6157464623230.5—
Cash-flow statement
Depreciation and amortization7.37.26.85.74.84.34.84.55.05.7
Share-based compensation142525262312102.91.41.0
Cash from operating activities−177−192−1123.5−82−68−6513−37−13
Capital expenditure———————−1.6−3.3−4.4
Cash from investing activities45219−3.9−35−970.6−51−80339.6
Debt issued—————25—0150
Debt repaid0−4.1−13−9.4—−10−5.0———
Shares issued0250r0r—251−0.3———
Shares bought back————−0.0—————
Cash from financing activities0.094138483.3269−4.2171150.2
Change in cash−1321212217−176202−12010310−3.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Sutro Biopharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Restructuring 2 · Directors and officers 4 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11

Sutro Biopharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Agreement endedResults announced8-K
Material agreement8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Restructuring8-K
Results announced8-K
Delisting notice8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
RestructuringDirectors and officersResults announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Sutro Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$85 MNo. 1$50 to $250 million15equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Sutro Biopharma, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $162 K a year.

Certified, FY2026
1
#1,856 among companies on value.today
Worker positions
1
Median wage offered
$162 K
a year, full-time
Applications filed
1
Sutro Biopharma, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Sr. ScientistMedical Scientists, Except Epidemiologists1$162 K

Where: South San Francisco, CA 1

Sutro Biopharma, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$162 K1
FY202566$189 K6
FY202466$156 K6
FY202377$140 K7
FY202222$171 K2
FY202133$211 K3
FY202022$136 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Sutro Biopharma, Inc.

Layoffs at Sutro Biopharma, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
119
2025–2025
Latest
—
2025-09-29
Sutro Biopharma, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025··65·····54···119
Sutro Biopharma, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
effective 45 peopleLayoffWARN noticeSouth San Francisco, CaliforniaNotice list
effective 8 peopleLayoffWARN noticeSan Carlos, CaliforniaNotice list
effective 1 personLayoffWARN noticeSan Mateo County, CaliforniaNotice list
50% of workforceRestructuring planSEC 8-K“The Company also plans to reduce its workforce by approximately 50%.”Filing
effective 62 peopleLayoffWARN noticeSan Carlos, CaliforniaNotice list

Source: State WARN notices and SEC 8-K item 2.05

How Sutro Biopharma, Inc. compares in Biotechnology

  • Market cap$155 M · higher than 41% of 726
  • Revenue$102 M · higher than 69% of 647
  • Net margin-186.5% · higher than 29% of 408
  • Revenue growth65.2% · higher than 78% of 438
  • Price / sales1.5× · lower than 90% of 339
  • FCF yield7.2% · higher than 97% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Sutro Biopharma, Inc.🇺🇸$155 M—-186.5%+65.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sutro Biopharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sutro Biopharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sutro Biopharma, Inc.? Suggest a correction